Soligenix Inc (SNGX) Stock Analysis

Verdict: AVOID

Terminal cash burn and 93% price collapse signal a failing micro-cap biotech; without a major funding or FDA catalyst, dilution is certain.

Investment score: 18/100

Analysis as of 2026-06-06

Is Soligenix Inc stock worth reviewing? The TradeMates thesis

Soligenix is a distressed micro-cap biotech with a 0.77 current ratio (adjusted for burn) and no path to near-term profitability. Technicals are broken, and the cash runway is critically short.

7-factor investment score

Valuation: 30/100 (weight 20%)
Financial Health: 10/100 (weight 15%)
Technical Momentum: 5/100 (weight 15%)
Earnings Quality: 25/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 20/100 (weight 10%)
Risk-Adjusted Return: 10/100 (weight 15%)

Soligenix Inc opportunities and risks

What speaks for SNGX

HyBryte Phase 3 Completion

What speaks against SNGX

Imminent Equity Dilution

Peers and competitors

AIM
PHGE
ACXP
XBIO
GNPX

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
SNGX	n/a	0.0x	0.1x	0.0%	0.0%	-235.9%
AIM	n/a	18.7x	n/a	-133.0%	-14123.4%	-659.5%
PHGE	n/a	0.0x	0.0x	0.0%	0.0%	-2012.8%
ACXP	n/a	0.0x	0.9x	0.0%	0.0%	-230.7%
XBIO	n/a	1.8x	0.6x	100.0%	-70.0%	-31.2%
GNPX	n/a	0.0x	1.1x	0.0%	0.0%	-1353.9%
Peer median	n/a	0.0x	0.6x	0.0%	0.0%	-659.5%

Frequently asked questions about Soligenix Inc (SNGX)

Is SNGX stock a good investment?

The TradeMates model rates Soligenix Inc as AVOID with an investment score of 18/100. Soligenix is a distressed micro-cap biotech with a 0.77 current ratio (adjusted for burn) and no path to near-term profitability. Technicals are broken, and the cash runway is critically short. This is algorithmic model output, not personal investment advice.

Is SNGX stock a buy?

The TradeMates model verdict for SNGX is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.